Announcements Trials

Browse Landscape

Status

Completed 2 Recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 52 Thoracic 33 Breast 33 Genitourinary 25 Gynecologic 23 Head & Neck 19 CNS 19 Tumor-Agnostic 17 Lymphoid 16 Sarcoma 13 Other hematologic neoplasm 11 Dermatologic 11 Plasma cell 5 Myeloid 5 Other solid neoplasm 3 Endocrine 2 NET 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 15 Magnetic Resonance Spectroscopy 9 Everolimus 8 gallium Ga 68 dotatate 6 lanreotide 4 cabozantinib 4 Temozolomide 4 Specimen Handling 4 Nivolumab 4 Lutetium-177 4 Lutetium 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 surufatinib 3 olaparib 3 copper dotatate CU-64 3 Somatostatin 3 Injections 3 Ga(III)-DOTATOC 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Capecitabine 3 pembrolizumab 2 fludarabine phosphate 2 fludarabine 2 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Sunitinib 2 Radiosurgery 2 Octreotide 2 Drug Therapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Blood Specimen Collection × NET × Clear all

NCT06430021 2026-05-22

PRO-NEM1

Centre Hospitalier Universitaire Dijon

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡